Text Size

The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose

This study is currently recruiting participants.
Verified June 2011 by Outcomes Research Consortium
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by:
Outcomes Research Consortium
ClinicalTrials.gov Identifier:
NCT01187329
First received: August 19, 2010
Last updated: June 13, 2011
Last verified: June 2011
History of Changes
  Purpose

The overall research plan is to test the hypothesis that intraoperative treatment of hyperinsulinemic normoglycemic clamp (HNC) in cardiac surgical patients improves myocardial function and short-term outcomes compared with standard glucose management.


Condition Intervention
Hyperglycemia
Coronary Artery Bypass Graft
Coronary Artery Bypass
 Other: hyperinsulinemic normoglycemic clamp (HNC)
Other: control group

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose

Resource links provided by NLM:

Drug Information available for: Dextrose
U.S. FDA Resources

Further study details as provided by Outcomes Research Consortium:

Primary Outcome Measures:
  • Myocardial function [ Time Frame: end of surgery, closure ] [ Designated as safety issue: No ]
    Myocardial function measured echocardiographically by global longitudinal systolic strain using speckle tracking imaging at end of surgery.


Secondary Outcome Measures:
  • diastolic function [ Time Frame: end of surgery, closure ] [ Designated as safety issue: No ]
    Echocardiographic measures of diastolic function, including transmitral deceleration time (EDT), velocity of propagation (vp) and intraventricular pressure gradients (IVPG).

  • myocardial systolic function [ Time Frame: Day 3 - Day 5, post operative ] [ Designated as safety issue: No ]
    Additional echocardiographic measures of myocardial systolic function, such as myocardial velocities measured by tissue Doppler imaging and left ventricular ejection fraction (LVEF).


Estimated Enrollment: 100
Study Start Date: October 2010
Estimated Study Completion Date: October 2012
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: hyperinsulinemic normoglycemic clamp (HNC)
Patients will be randomized to receive treatment with HNC during cardiac surgery.
 Other: hyperinsulinemic normoglycemic clamp (HNC)
Prior to anesthetic induction, a baseline blood glucose value will be obtained, followed by an insulin infusion of 5 mU.Kg-1.min-1. When blood glucose is <110 mg/dL, a variable continuous infusion of glucose (dextrose 20%) supplemented with potassium (40 mEq/L) and phosphate (30 mmol/L) is administered to preserve normoglycemia (80-110 mg/dL). The glucose infusion is titrated to target glucose levels by checking blood glucose every 5 - 15 min with Accu-Check (Roche Diagnostics, Switzerland) glucose monitor. At sternal closure, insulin infusion is decreased to 1 mU/Kg/min. On admission to the ICU, insulin treatment follows the ICU protocol. The dextrose infusion is slowly weaned off over 2 - 4 hrs maintaining blood glucose > 80 mg/dL. Arterial blood glucose is measured every 30 - 60 min for 2 hrs, then, as stated in ICU protocol.
Placebo Comparator: standard glucose management
Patients will be randomized to receive treatment with standard glucose management during cardiac surgery.
 Other: control group
Baseline arterial blood glucose will be obtained before anesthetic induction. Repeat measurements are performed every 30-90 min. Glucose >150 on CPB will receive insulin according to intraoperative protocol. After surgery, insulin is given according to ICU protocol.
Other Names:
  • glucose
  • standard of care

  Eligibility

Ages Eligible for Study:   50 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 50 - 75 years old
  • Scheduled for Coronary Artery Bypass Graft(CABG) requiring Cardiopulmonary Bypass(CPB) and cardioplegic arrest
  • Left ventricular dysfunction documented by left ventricular ejection fraction (LVEF) 40% by preoperative echocardiogram

Exclusion Criteria:

  • Off -pump surgical procedure
  • Anticipated deep hypothermic circulatory arrest
  • Any contraindications to transesophageal echocardiogram (TEE) or other proposed intervention
  • Unable to give written informed consent (non-English speaking, vulnerable patients, etc.)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01187329

Contacts
Contact: Gretchen Upton 216-444-3289 uptong@ccf.org

Locations
United States, Ohio
Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Principal Investigator: Andra Duncan, MD            
Sponsors and Collaborators
Outcomes Research Consortium
National Institutes of Health (NIH)
  More Information

No publications provided

Responsible Party: Andra Duncan, MD, Cleveland Clinic Foundation
ClinicalTrials.gov Identifier: NCT01187329     History of Changes
Other Study ID Numbers: 10-526
Study First Received: August 19, 2010
Last Updated: June 13, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Outcomes Research Consortium:
Hyperglycemia
open heart surgery
bypass

Additional relevant MeSH terms:
Hyperglycemia
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 23, 2013